JP7072519B2 - Ｂｅｔタンパク質分解剤 - Google Patents

Ｂｅｔタンパク質分解剤 Download PDF

Info

Publication number
JP7072519B2
JP7072519B2 JP2018553365A JP2018553365A JP7072519B2 JP 7072519 B2 JP7072519 B2 JP 7072519B2 JP 2018553365 A JP2018553365 A JP 2018553365A JP 2018553365 A JP2018553365 A JP 2018553365A JP 7072519 B2 JP7072519 B2 JP 7072519B2
Authority
JP
Japan
Prior art keywords
group
compound
optionally substituted
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018553365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511528A (ja
JP2019511528A5 (cg-RX-API-DMAC7.html
Inventor
シャオメン ワン
ビン チョウ
フーミン スー
ジャンタオ フー
ロンチュアン バイ
チャオ－イエ ヤン
Original Assignee
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン filed Critical ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン
Publication of JP2019511528A publication Critical patent/JP2019511528A/ja
Publication of JP2019511528A5 publication Critical patent/JP2019511528A5/ja
Application granted granted Critical
Publication of JP7072519B2 publication Critical patent/JP7072519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2018553365A 2016-04-12 2017-04-06 Ｂｅｔタンパク質分解剤 Active JP7072519B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662321499P 2016-04-12 2016-04-12
US62/321,499 2016-04-12
US201662393888P 2016-09-13 2016-09-13
US62/393,888 2016-09-13
PCT/US2017/026278 WO2017180417A1 (en) 2016-04-12 2017-04-06 Bet protein degraders

Publications (3)

Publication Number Publication Date
JP2019511528A JP2019511528A (ja) 2019-04-25
JP2019511528A5 JP2019511528A5 (cg-RX-API-DMAC7.html) 2020-05-14
JP7072519B2 true JP7072519B2 (ja) 2022-05-20

Family

ID=58548921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553365A Active JP7072519B2 (ja) 2016-04-12 2017-04-06 Ｂｅｔタンパク質分解剤

Country Status (15)

Country Link
US (1) US10633386B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442976B1 (cg-RX-API-DMAC7.html)
JP (1) JP7072519B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180132861A (cg-RX-API-DMAC7.html)
CN (1) CN109311890B (cg-RX-API-DMAC7.html)
AU (1) AU2017250076B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070859A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020541A1 (cg-RX-API-DMAC7.html)
IL (1) IL262139B (cg-RX-API-DMAC7.html)
MX (1) MX384905B (cg-RX-API-DMAC7.html)
RU (1) RU2752677C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201808729WA (cg-RX-API-DMAC7.html)
UA (1) UA123168C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017180417A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201806969B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445357B1 (en) 2016-04-22 2021-05-26 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
AU2017281903B2 (en) * 2016-06-23 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN109422751B (zh) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROQUINOLINONES
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
JP2021502388A (ja) * 2017-11-10 2021-01-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
EP3841098A4 (en) 2018-08-22 2022-05-04 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHOD OF USE
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
JP7168773B2 (ja) * 2018-09-30 2022-11-09 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ イソインドリン化合物、その調製方法、医薬組成物および使用
JP7631191B2 (ja) * 2018-10-09 2025-02-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｅ３リガーゼの共有結合による標的化
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
CA3126009A1 (en) * 2019-01-07 2020-07-16 Dana-Farber Cancer Institute, Inc. Small molecule degraders of fkbp12 via recruitment of von hippel-lindau e3 ubiquitin ligase (vhl) e3 ubiquitin ligase, and uses in dtag systems
JP2022521453A (ja) * 2019-01-22 2022-04-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 複素環式の誘導体
EP4029499A4 (en) * 2019-06-12 2023-07-26 Shanghaitech University Alk protein regulator and anti-tumor application thereof
CN120623106A (zh) * 2019-09-30 2025-09-12 协和麒麟株式会社 Bet降解剂
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
CN115697989B (zh) 2020-02-26 2025-03-18 上海睿跃生物科技有限公司 原肌球蛋白受体激酶(trk)降解化合物和使用方法
EP4114392A4 (en) 2020-03-05 2024-04-10 C4 Therapeutics, Inc. Compounds for targeted degradation of brd9
CN113387932B (zh) * 2020-03-14 2023-05-09 成都先导药物开发股份有限公司 一种诱导brd4蛋白降解的双功能化合物
CN112920176B (zh) * 2020-05-25 2022-11-04 四川大学华西医院 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
WO2022051616A1 (en) * 2020-09-03 2022-03-10 Board Of Regents Of The University Of Nebraska Cdk targeted heterobifunctional small molecule proteolysis targeting chimeras
AR125768A1 (es) 2021-05-05 2023-08-09 Biogen Ma Inc Compuestos para la degradación dirigida de la tirosina cinasa de bruton
CN113336801B (zh) * 2021-06-08 2023-08-22 中国人民解放军空军军医大学 含有bet抑制剂的四价铂配合物与应用
EP4366834A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
US20240343733A1 (en) 2021-07-07 2024-10-17 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
CA3260847A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen Alpha Receptor Degrading Agents and Their Uses
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
CN116585322B (zh) * 2023-01-16 2023-10-13 中山大学中山眼科中心 Bet蛋白降解剂在预防和治疗视网膜退行性改变相关疾病中的应用
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202502779A (zh) 2023-06-30 2025-01-16 美商金橘生物科技公司 取代的雜芳族胺及其用途
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2025096855A1 (en) 2023-11-02 2025-05-08 Kumquat Biosciences Inc. Degraders and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164596A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
WO2015131005A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
US20150291562A1 (en) 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001011A1 (en) 1980-09-24 1982-04-01 Corp Cetus Diagnostic method and probe
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
ATE227727T1 (de) 1996-09-13 2002-11-15 Mitsubishi Pharma Corp Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
FR2843126B1 (fr) 2002-08-01 2006-01-27 Cis Bio Int "methode de determination d'une activite enzymatique endoglycosidase"
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
DK2118074T3 (en) 2007-02-01 2014-03-10 Resverlogix Corp Compounds for the prevention and treatment of cardiovascular diseases
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
EP2346837B8 (en) 2008-06-26 2015-04-15 Resverlogix Corporation Methods of preparing quinazolinone derivatives
EP3354646A1 (en) * 2008-10-29 2018-08-01 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
EP2421533B1 (en) 2009-04-22 2018-10-17 Resverlogix Corp. Novel anti-inflammatory agents
DE102009051823A1 (de) 2009-11-04 2011-05-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Einkristallines Schweißen von direktional verfestigten Werkstoffen
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
CN102781943B (zh) 2009-11-05 2016-10-05 葛兰素史密丝克莱恩有限责任公司 苯并二氮杂*溴结构域抑制剂
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
LT3202461T (lt) * 2010-02-11 2019-04-25 Celgene Corporation Arilmetoksiizoindolino dariniai ir juos apimančios kompozicijos bei jų panaudojimo būdai
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
CN103547152A (zh) 2011-02-23 2014-01-29 西奈山伊坎医学院 溴结构域蛋白的抑制剂作为基因表达的调节剂
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
DE102011082013A1 (de) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
JP5989229B2 (ja) 2012-04-20 2016-09-07 アッヴィ・インコーポレイテッド イソインドロン誘導体
JP6215315B2 (ja) 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
EP2961735B1 (en) * 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
US10307407B2 (en) * 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
WO2017030814A1 (en) * 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CA3020281A1 (en) * 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508414A (ja) 2012-01-12 2015-03-19 イエール ユニバーシティ Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法
WO2014164596A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
WO2015131005A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
US20150291562A1 (en) 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Winter, Georg E. et al，Phthalimide conjugation as a strategy for in vivo target protein degradation，Science，2015年，348 (6241)，1376-1381
Zengerle, Michael; Chan, Kwok-Ho; Ciulli, Alessio，Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4，ACS Chemical Biology，2015年，10 (8)，1770-1777

Also Published As

Publication number Publication date
UA123168C2 (uk) 2021-02-24
US10633386B2 (en) 2020-04-28
US20190169195A1 (en) 2019-06-06
IL262139B (en) 2021-05-31
MX384905B (es) 2025-03-14
RU2018139537A3 (cg-RX-API-DMAC7.html) 2020-08-11
EP3442976B1 (en) 2022-07-20
SG11201808729WA (en) 2018-11-29
RU2018139537A (ru) 2020-05-14
AU2017250076A1 (en) 2018-11-08
JP2019511528A (ja) 2019-04-25
RU2752677C2 (ru) 2021-07-29
EP3442976A1 (en) 2019-02-20
MX2018012379A (es) 2019-07-04
CN109311890A (zh) 2019-02-05
IL262139A (en) 2018-11-29
CN109311890B (zh) 2021-08-31
CA3020541A1 (en) 2017-10-19
AU2017250076B2 (en) 2021-07-22
BR112018070859A2 (pt) 2019-02-05
WO2017180417A1 (en) 2017-10-19
KR20180132861A (ko) 2018-12-12
ZA201806969B (en) 2019-12-18

Similar Documents

Publication Publication Date Title
JP7072519B2 (ja) Ｂｅｔタンパク質分解剤
JP6961684B2 (ja) Ｂｅｔタンパク質分解物質としての縮合１，４−オキサゼピン
JP7037500B2 (ja) Ｍｄｍ２タンパク質分解剤
JP7035027B2 (ja) Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン
JP6991585B2 (ja) メニン阻害剤としてのピペリジン
JP7094566B2 (ja) Ａｌｋ阻害剤としてのアミノピリミジン類
CN110914265B (zh) 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
JP2017511801A (ja) ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
JP2022502409A (ja) 低分子メニン阻害剤
US11267822B2 (en) BET bromodomain protein degraders with cleavable linkers
HK40004858A (en) Bet protein degraders
HK40004858B (en) Bet protein degraders
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200403

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220317

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220317

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220328

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220413

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220510

R150 Certificate of patent or registration of utility model

Ref document number: 7072519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150